Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report) – Equities research analysts at HC Wainwright increased their Q3 2026 EPS estimates for Dianthus Therapeutics in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($1.00) for the quarter, up from their previous estimate of ($1.43). HC Wainwright has a “Buy” rating and a $158.00 price target on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($3.83) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q4 2026 earnings at ($1.11) EPS, FY2026 earnings at ($3.87) EPS, Q1 2027 earnings at ($1.26) EPS, Q2 2027 earnings at ($1.39) EPS, Q3 2027 earnings at ($1.51) EPS, Q4 2027 earnings at ($1.62) EPS, FY2027 earnings at ($5.77) EPS, FY2028 earnings at ($7.60) EPS, FY2029 earnings at ($0.13) EPS and FY2030 earnings at $10.75 EPS.
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). The company had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%.
View Our Latest Report on DNTH
Dianthus Therapeutics Price Performance
DNTH stock opened at $111.80 on Monday. Dianthus Therapeutics has a 1 year low of $18.08 and a 1 year high of $114.55. The company has a market cap of $6.11 billion, a P/E ratio of -26.94 and a beta of 1.22. The stock’s fifty day moving average price is $95.17 and its 200-day moving average price is $81.36.
Insider Transactions at Dianthus Therapeutics
In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 26,530 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $90.62, for a total value of $2,404,148.60. Following the transaction, the executive vice president owned 4,000 shares of the company’s stock, valued at $362,480. This represents a 86.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Ryan Savitz sold 31,249 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the completion of the sale, the executive vice president directly owned 31,249 shares of the company’s stock, valued at $3,157,086.47. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 253,779 shares of company stock valued at $25,931,495 over the last three months. Corporate insiders own 3.02% of the company’s stock.
Hedge Funds Weigh In On Dianthus Therapeutics
A number of large investors have recently bought and sold shares of the business. PNC Financial Services Group Inc. grew its position in Dianthus Therapeutics by 0.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock worth $3,135,000 after purchasing an additional 139 shares during the last quarter. First Horizon Corp purchased a new position in shares of Dianthus Therapeutics in the first quarter worth $32,000. Virtus Investment Advisers LLC lifted its stake in shares of Dianthus Therapeutics by 7.1% during the fourth quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock worth $260,000 after buying an additional 416 shares during the period. Royal Bank of Canada lifted its stake in shares of Dianthus Therapeutics by 36.9% during the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after buying an additional 542 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Dianthus Therapeutics by 4.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after buying an additional 618 shares during the period. Institutional investors own 47.53% of the company’s stock.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.
Featured Stories
- Five stocks we like better than Dianthus Therapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
